Compare Lamb Weston Holdings Inc (LW) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs Organon & Co. Common Stock — how do they compare? Lamb Weston Holdings Inc trades at $53.22 (market cap $7.16B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Lamb Weston Holdings Inc is the larger of the two by market cap, and Lamb Weston Holdings Inc pays the higher dividend (2.93%). Which is the better fit depends on your goals — on Pluang, investors hold Lamb Weston Holdings Inc for 66 Days and Organon & Co. Common Stock for 0 Days on average.
| LW | OGN | |
|---|---|---|
Market Cap | $7.16B | $3.62B |
Volume | 2,766,229 | 2,892,999 |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $13.81 |
52-Week Low | $38.48 | $5.70 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $10.95B | $11.04B |
Dividend Yield | 2.93% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $53.02, up 5.66% today, near the consensus price target of $53.71. The stock shows bullish technical signals with strong moving averages and recent earnings beats. Revenue reached $6.45B in 2025, though net income margin compressed to 3.85%. The company maintains a solid balance sheet with $70.70M cash and ongoing dividend payments of $0.38 per share.
Outlook remains mixed; analyst consensus leans Hold (63%) with potential upside to $58.00. Key risks include margin pressure from high debt and volatile earnings. Positive sentiment from cost-saving initiatives supports recovery, but investor confidence hinges on sustained profitability improvements amid competitive pressures.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
